Moxalactam Disodium | CAS#64953-12-4 | beta-lactam antibiotic

MedKoo Cat#: 562009 | Name: Moxalactam Disodium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Moxalactam Disodium is a broad- spectrum beta-lactam antibiotic.

Chemical Structure

Moxalactam Disodium

CAS#64953-12-4 (sodium)

Theoretical Analysis

MedKoo Cat#: 562009

Name: Moxalactam Disodium

CAS#: 64953-12-4 (sodium)

Chemical Formula: C20H18N6Na2O9S

Exact Mass: 564.0651

Molecular Weight: 564.44

Elemental Analysis: C, 42.56; H, 3.21; N, 14.89; Na, 8.15; O, 25.51; S, 5.68

Price and Availability

Size	Price	Availability
200mg	USD 250.00	2 Weeks
500mg	USD 450.00	2 Weeks
1g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

64953-12-4 (sodium) 64952-97-2 (free acid)

Synonym

Moxalactam Disodium; Latamoxef, Sodium Salt;

IUPAC/Chemical Name

sodium (6R,7R)-7-(2-carboxylato-2-(4-hydroxyphenyl)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

InChi Key

GRIXGZQULWMCLU-HUTAOCTPSA-L

InChi Code

InChI=1S/C20H20N6O9S.2Na/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9;;/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32);;/q;2*+1/p-2/t12?,18-,20+;;/m1../s1

SMILES Code

OC1=CC=C(C(C(N[C@@]2(C(N3[C@@H]2OCC(CSC4=NN=NN4C)=C3C(O[Na])=O)=O)OC)=O)C(O[Na])=O)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Moxalactam (Latamoxef) sodium salt is a synthetic oxa-β-lactam antibiotic.

In vitro activity:

The minimum inhibitory concentrations of MOX (moxalactam), CTX, and CFZ/SBT against E. coli ATCC25922, 3376, and 2689 strains were 0.5, 0.5, 0.25; 0.06, >256, 256; and 0.5/0.5, 16/16, 32/32 mg/L. All the agents demonstrated outstanding bactericidal effects against E. coli ATCC25922 (RT >24 h and IE >120 log10 CFU/mL·h-1) with simulating PK procedures, especially in the multiple dose administration models. MOX exhibited potent antibacterial activity against all the strains tested. The values of effective parameters of MOX were much higher than those of CTX and CFZ/SBT (the bacterial RTs with the 3 agents were >24, <4, and <13 h, and the IEs were >110, <10, and <60 log10 CFU/mL·h-1, respectively). Reference: Infect Drug Resist. 2018 Jan 15;11:103-112. https://pubmed.ncbi.nlm.nih.gov/29391816/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	55.8	98.92
	Water	83.3	147.64

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 564.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Huang C, Zheng B, Yu W, Niu T, Xiao T, Zhang J, Xiao Y. Antibacterial effect evaluation of moxalactam against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation. Infect Drug Resist. 2018 Jan 15;11:103-112. doi: 10.2147/IDR.S150431. PMID: 29391816; PMCID: PMC5772397. 2. Quan JJ, Wang Y, Ji JS, Wang YF, Wang HP, Xu YC, Yu YS. [The activity of moxalactam against Enterobacteriaceae and anaerobia in vitro]. Zhonghua Yi Xue Za Zhi. 2016 May 17;96(18):1459-64. Chinese. doi: 10.3760/cma.j.issn.0376-2491.2016.18.015. PMID: 27266357.

In vitro protocol:

In vivo protocol:

TBD

1: Abdul-Fattah AM, Dellerman KM, Bogner RH, Pikal MJ. The effect of annealing on the stability of amorphous solids: chemical stability of freeze-dried moxalactam. J Pharm Sci. 2007 May;96(5):1237-50. PubMed PMID: 17455341. 2: Inagaki K, Kambara M, Mizuno M, Okuda J, Gill MA, Nishida M. Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated y-site administration. Int J Pharm Compd. 1998 Jul-Aug;2(4):318-21. PubMed PMID: 23989642. 3: Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA. Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan. Arch Surg. 1991 Apr;126(4):524-5. PubMed PMID: 1901205. 4: Bissett IP, Isbister WH. Single dose prophylaxis in colorectal surgery. N Z Med J. 1990 Sep 12;103(897):428-9. PubMed PMID: 2395570. 5: Soback S. Pharmacokinetics of single-dose administration of moxalactam in unweaned calves. Am J Vet Res. 1989 Apr;50(4):498-501. PubMed PMID: 2653122. 6: Vaala WE, Clark ES, Orsini JA. Omphalophlebitis and osteomyelitis associated with Klebsiella septicemia in a premature foal. J Am Vet Med Assoc. 1988 Nov 15;193(10):1273-7. PubMed PMID: 3204051. 7: Rapp RP, Connors JE, Hager WD, Donaldson ES, van Nagell JR Jr. Comparison of single-dose moxalactam and a three-dose regimen of cefoxitin for prophylaxis in vaginal hysterectomy. Clin Pharm. 1986 Dec;5(12):988-93. PubMed PMID: 3542346. 8: Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M. Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. PubMed PMID: 3778044. 9: Dashow EE, Read JA, Coleman FH. Randomized comparison of five irrigation solutions at cesarean section. Obstet Gynecol. 1986 Oct;68(4):473-8. PubMed PMID: 3748494. 10: Vowden P, Stewart J, Fowler B, Ramsden CH, Kester RC. The concentration of latamoxef achieved in the bile and gallbladder wall of patients with cholecystitis. J Antimicrob Chemother. 1986 Aug;18(2):227-32. PubMed PMID: 3759734. 11: Nelson RM, Benitez PR, Newell MA, Wilson RF. Single-antibiotic use for penetrating abdominal trauma. Arch Surg. 1986 Feb;121(2):153-6. PubMed PMID: 3947216. 12: Spruill WJ, McCall CY, Francisco GE. In vitro inactivation of tobramycin by cephalosporins. Am J Hosp Pharm. 1985 Nov;42(11):2506-9. PubMed PMID: 3907338. 13: Majercik PL, May JR, Longe RL, Johnson MH. Evaluation of pharmacy and therapeutics committee drug evaluation reports. Am J Hosp Pharm. 1985 May;42(5):1073-6. PubMed PMID: 4003418. 14: Crots LD, Obeid FN, Horst HM, Bivins BA. Twice-daily moxalactam versus gentamicin and clindamycin in patients with penetrating abdominal trauma. Clin Pharm. 1985 May-Jun;4(3):316-20. PubMed PMID: 3891203. 15: Brandstetter RD, Tamarin FM, Rangraj MS, Ruiz M, Giampietro J. Moxalactam disodium-induced pulmonary hemorrhage. Chest. 1984 Oct;86(4):644-5. PubMed PMID: 6478911. 16: Fainstein V, Bodey GP, Bolivar R, Elting L, McCredie KB, Keating MJ. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med. 1984 Sep;144(9):1766-70. PubMed PMID: 6383246. 17: Fett DR, Silverman CA, Yoshizumi MO. Moxalactam retinal toxicity. Arch Ophthalmol. 1984 Mar;102(3):435-8. PubMed PMID: 6608344. 18: Au JP, Geiger GS. Thrombocytopenia associated with moxalactam administration. Drug Intell Clin Pharm. 1984 Feb;18(2):140-2. PubMed PMID: 6697876. 19: Joehl RJ, Rasbach DA, Ballard JO, Weitekamp MR, Sattler FR. Moxalactam. Evaluation of clinical bleeding in patients with abdominal infection. Arch Surg. 1983 Nov;118(11):1259-61. PubMed PMID: 6639335. 20: Fass RJ. Comparative in vitro activities of third-generation cephalosporins. Arch Intern Med. 1983 Sep;143(9):1743-5. PubMed PMID: 6615095.